ArticleJournal of natural medicines2026
Extracts of okra mucilage protect intestinal homeostasis through gut microbiota and immune responses.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Okra pods (Abelmoschus esculentus (L.) Moench) are known as a vegetable, the mucilage of which possesses many bioactivities. Okra mucilage (OM) is a carbohydrate-rich natural extract containing polysaccharides and other bioactive components. However, its efficacy under different types of intestinal stress and its comparison with standard therapeutic agents remain unclear. Chemical characterization demonstrated that OM contains abundant carbohydrates and diverse chemical constituents. In this study, we evaluated the protective effects of OM in dextran sulfate sodium (DSS)-induced colitis and fasting-induced intestinal injury models in mice. Mesalazine and GA were used as a positive control in DSS and fasting-induced injury models, respectively. Generally, OM treatment significantly alleviated intestinal pathological damage, restored intestinal barrier integrity, promoted epithelial regeneration, and modulated gut microbial composition in these two models. In DSS-induced colitis, OM increased the abundance of short-chain fatty acid (SCFA)-producing bacterial families Muribaculaceae and Lachnospiraceae, while reducing pro-inflammation-associated Bacteroidaceae, and suppressed key inflammatory genes and factors, including Cxcl1, Cxcl2, Cxcl5, TNF, NF-κB. Notably, the regulatory effects of OM were comparable to mesalazine. In fasting-induced intestinal injury, OM restored microbial balance by regulating taxa such as Enterobacteriaceae and Erysipelotrichaceae, and downregulated gluconeogenesis-related genes including Klf15, Pck1, and Hmgcs2. OM upregulated genes involved in epithelial barrier function and immune homeostasis such as Btnl7, Btnl8, regulating pathways HIF-1, PI3K-Akt, MAPK and glycolysis/gluconeogenesis pathways. These findings demonstrate that OM alleviates intestinal injury by modulating gut microbiota, suppressing inflammation, and restoring intestinal immune and metabolic homeostasis, highlighting its potential as a natural mucilage-derived ingredient for maintaining intestinal homeostasis.
Indexed as
Identifiers
42830374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.